Kowa is showcasing the AP 7000 automatic perimeter at Vision Expo West as one of the most elite, quality products in its class. The AP 7000’s standard built-in database of normal eyes with a measured periphery of 60°, enables more precise judgment of periphery test results. The AP7000 can be used to apply a static perimetry test to abnormal sites on a fundus image, such as a fundus photograph, OCT or SLO. The AP-7000 is equipped with analytical indices in line with the guidelines for glaucoma.
Acting as an isopter and screening device to performing fundus oriented perimetry and its unique network linkage capabilities, the AP 7000 is unlike any other. The all-encompassing automatic perimeter by Kowa has every feature necessary to access efficient, accurate information.
For more general and purchasing information regarding the AP 7000 please join Kowa at booth MS6051 at 2012 Vision Expo West or visit: www.kowa-usa.com
TV personality John O’Hurley, along with the National Lipid Association (NLA), Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company, announced the results of the USAGE survey, “Understanding Statin use in America and Gaps in Education.” USAGE is the largest known U.S. survey involving more than 10,100 statin users and is the first major survey to provide data on why patients stop taking their cholesterol statin medications, the most commonly prescribed medication to treat high cholesterol.
Seinfeld actor and Dancing with the Stars contestant, John O’Hurley has taken the role of public spokesperson for the USAGE campaign due to his own diagnosis of high-cholesterol. Upon becoming an active member of the USAGE team O’Hurley stated “millions of people, like me, are affected by high cholesterol, and it’s my hope that the USAGE survey gives them clearer direction on how to bring up concerns with their doctor.” Off the set he has dedicated himself to public health causes including his position as Public Relations Director of The Red Cross.
Currently doctors write more than 200 million prescriptions for statins each year however, patients actually adhering to and continuing statin treatment remains a major issue. Most commonly problems with statin adherence are associated with an increased risk of negative cardiovascular results, including heart disease and death. USAGE recorded 62% of responses listing side-effects as the reason for stopping treatment. An additional 17% stated cost was their reason for terminating statin treatment. A lack of treatment effectiveness was listed as third most important.
Research indicates that nearly 75% of new statin users stop therapy by the end of the first year. Among all those that did end their treatment, 34% admitted to not consulting their doctor first about ended statin treatment. Ironically enough, 81% of patients surveyed reported being satisfied with their doctor’s explanation of treatment.
The USAGE survey has been created in order to fill the gaps in statin treatment education. The USAGE website provides downloadable tools and resources, including patient directed discussion guides and a medication tracker. Also included is a presentation for healthcare providers to educate the medical community about the USAGE survey and its findings.
Kowa Company Ltd. is comprised of Kowa Pharmaceuticals America, Inc., Kowa Optimed and Kowa Health Care. Kowa Pharmaceudicals America is the entity directly involved with USAGE. Kowa Pharmaceutical specializes primarily in the area of cardiometabolic diseases. A privately held company, KPA focuses its attention towards the acquisition, licensing and marketing of pharmaceutical products.
Kowa Optimed is encouraging submission for the upcoming Ocular Imaging Challenge hosted by The Office of the National Coordinator for Health Information Technology. According to the OIC homepage, this challenge calls innovators and software developers to “create an application that improves interoperability among office-based ophthalmic imaging devices, measurement devices, and EHRs.” The application process began May 14, 2012 and will close on November 9, 2012.
For this challenge, ONC has required necessary attributes for first place. The application should convert output from legacy ophthalmic imaging and measurement devices from proprietary formats to vendor-neutral standard formats. The application should also be able to archive data from multiple imaging and measurement devices. Images and data should be displayed for clinicians and permit basic functionalities such as optimizing viewing parameters. For example, settings such as brightness and contrast should be adjustable for viewing ease. Finally, the application should generate integration with existing EHRs (Existing Health Records). Where applicable, the application should additionally leverage and extend NwHIN (Nationwide Health Information Network) standards and services.
All applicants will be reviewed by the ONC review panel during the four day evaluation period (November 16, 2012-November 20, 2012). Selections will be based collectively on the previously mentioned criteria and other standards such as mobile usability, functionality, accuracy, security and general practicality. Categories for selection have been labeled as, breadth of input devices and formats, usability and interface for image viewing, integration with workflow and platform neutrality.
OIC is offering a total of $150,000 in prize money to its first, second and third place winners. First place will not only receive $100,000 but also win conference exhibition opportunity. Second and third place will receive $35,000 and $15,000 respectively.
Craig Ross, President of Kowa Optimed, voiced his positive opinion of Kowa’s involvement in the OIC stating, “It’s important to take a leadership position with ocular imaging technology. These contestants are creating the next platform for ocular technology and eye health.”
For more information regarding the Ocular Imaging Challenge visit: http://challenge.gov/ONC/363-ocular-imaging-challenge